ECSP085573A - COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCOMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE TASA Y UN AGENTE ESTABILIZANTE - Google Patents

COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCOMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE TASA Y UN AGENTE ESTABILIZANTE

Info

Publication number
ECSP085573A
ECSP085573A EC20080055732008005573A ECSP085573A ECSP085573A EC SP085573 A ECSP085573 A EC SP085573A EC 20080055732008005573 A EC20080055732008005573 A EC 20080055732008005573A EC SP085573 A ECSP085573 A EC SP085573A EC SP085573 A ECSP085573 A EC SP085573A
Authority
EC
Ecuador
Prior art keywords
inhibitor
stabilizing agent
hmg
cholesterol
coa
Prior art date
Application number
EC20080055732008005573A
Other languages
English (en)
Inventor
Wing-Kee Philip Moore Will Chu
Shaun Fitzpatrick
Christian Seiler
Robert Saklatvala
Catherine R Petts
Original Assignee
Merck Sharp & Dohme
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP085573(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Schering Corp filed Critical Merck Sharp & Dohme
Publication of ECSP085573A publication Critical patent/ECSP085573A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Una composición farmacéutica que comprende una mezUna composición farmacéutica que comprende de 1% a 20% por peso de un inhibidor de absorción de colecla de gránulos de ezetimibe y gránulos de simvastatina, en donde los gránulos de ezetimibe y los grsterol, de 1% a 80% por peso de simvastatina, de 0.01% a 2% por peso de al menos un agente estabilizánulos de simvastatina comprenden cada uno lactosaante y hasta un máximo del 10% por peso de ácido c, celulosa microcristalina, corscarmelosa sódica, povidona, BHA, ácido ascórbico y ácido cítrico. ítrico, siempre que la composición no comprenda ácido ascórbico.
EC20080055732008005573A 2002-07-26 2008-02-28 COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCOMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE TASA Y UN AGENTE ESTABILIZANTE ECSP085573A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39869102P 2002-07-26 2002-07-26

Publications (1)

Publication Number Publication Date
ECSP085573A true ECSP085573A (es) 2008-03-26

Family

ID=31188454

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2005005573A ECSP055573A (es) 2002-07-26 2005-01-25 COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE
EC20080055732008005573A ECSP085573A (es) 2002-07-26 2008-02-28 COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCOMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE TASA Y UN AGENTE ESTABILIZANTE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2005005573A ECSP055573A (es) 2002-07-26 2005-01-25 COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE

Country Status (39)

Country Link
US (4) US7229982B2 (es)
EP (2) EP1531805B1 (es)
JP (2) JP2005538104A (es)
KR (2) KR20080070089A (es)
CN (2) CN1310643C (es)
AR (2) AR040588A1 (es)
AT (1) ATE393628T1 (es)
AU (2) AU2003261217B2 (es)
BR (1) BR0312933A (es)
CA (1) CA2493076A1 (es)
CR (1) CR9767A (es)
DE (1) DE60320652T2 (es)
DK (1) DK1531805T3 (es)
EA (1) EA008888B1 (es)
EC (2) ECSP055573A (es)
ES (1) ES2303603T3 (es)
GE (1) GEP20084443B (es)
GT (2) GT200300149A (es)
HK (1) HK1080384A1 (es)
HR (2) HRP20050081A2 (es)
IL (2) IL166279A0 (es)
IS (1) IS7637A (es)
MA (1) MA27289A1 (es)
ME (3) MEP4708A (es)
MX (1) MXPA05001004A (es)
MY (1) MY148689A (es)
NO (2) NO20051033L (es)
NZ (1) NZ537611A (es)
PA (1) PA8577901A1 (es)
PE (1) PE20050128A1 (es)
PL (1) PL375065A1 (es)
PT (1) PT1531805E (es)
RS (2) RS50419B (es)
SI (1) SI1531805T1 (es)
TN (1) TNSN05022A1 (es)
TW (2) TW200412944A (es)
UA (1) UA82489C2 (es)
WO (1) WO2004010993A1 (es)
ZA (1) ZA200500196B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2005047248A1 (en) * 2003-11-10 2005-05-26 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
US20070275075A1 (en) * 2006-03-06 2007-11-29 Ilan Zalit Ezetimibe compositions
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CN101677963B (zh) 2006-06-19 2012-05-30 奥尔制药公司 药物组合物
CN1994296B (zh) * 2006-08-02 2010-06-16 浙江京新药业股份有限公司 一种含有辛伐他汀的药物制剂
GB0713707D0 (en) 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
CA2694378A1 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
CN101938995A (zh) * 2007-12-17 2011-01-05 克卡制药新梅斯托股份公司 包含非微粉化依泽替米贝微粒的悬浮液
US20090233898A1 (en) * 2008-03-11 2009-09-17 Glenmark Generics Ltd Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe
TR200806302A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
WO2010066687A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Stabalized statin-comprising compositions
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011002422A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
WO2011002424A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
KR101302243B1 (ko) * 2010-07-28 2013-09-02 씨제이제일제당 (주) 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
CN101978953A (zh) * 2010-10-11 2011-02-23 上海交通大学 基于易吸湿性辅料的固体制剂
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
JP2014504630A (ja) 2011-02-02 2014-02-24 アルファーマ ファーマシューティカルズ エルエルシー オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物
CN102266323B (zh) * 2011-08-04 2013-03-27 海南锦瑞制药股份有限公司 依折麦布和辛伐他汀组合物及其制备方法
US9592296B2 (en) 2011-09-08 2017-03-14 Hexal Ag Pharmaceutical composition for oral administration with a statin
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
DK2844233T3 (da) * 2012-05-01 2020-07-13 Althera Life Sciences Llc Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
CN103585146B (zh) * 2013-11-09 2015-04-01 北京中申专利科技有限公司 辛伐他汀的药物组合物
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
CN104306348B (zh) * 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
CN108366957A (zh) * 2015-11-06 2018-08-03 燿石治疗公司 用于治疗心血管疾病的吉卡宾组合
CN106937952A (zh) * 2016-01-04 2017-07-11 重庆华邦制药有限公司 依折麦布和辛伐他汀的制剂
EP3281649A1 (en) * 2016-08-09 2018-02-14 Teleflex Lifesciences Wetting agent formulation
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
US11622939B2 (en) * 2017-11-23 2023-04-11 Zhejiang Hisun Pharmaceutical Co., Ltd. HS-25 tablet and preparation method therefor
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物
CN112168801A (zh) * 2020-10-22 2021-01-05 哈药集团技术中心 一种辛伐他汀片的制备方法
CN115227659B (zh) * 2022-08-19 2023-05-02 北京百奥药业有限责任公司 一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
AU1422388A (en) 1987-01-27 1988-08-10 Warner-Lambert Company Lipid regulating compositions
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
ES2107548T3 (es) 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
NZ245514A (en) * 1991-12-27 1994-12-22 Merck & Co Inc Controlled release drug delivery device comprising a core and a polymeric coating which is water impermeable but contains apertures to expose the core
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
JPH06247854A (ja) * 1993-02-24 1994-09-06 Ss Pharmaceut Co Ltd アスコルビン酸含有組成物
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
JPH10501811A (ja) * 1994-06-20 1998-02-17 シェーリング コーポレイション 低コレステロール化剤として有用な置換アゼチジノン化合物
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
MX9702175A (es) * 1994-09-20 1997-06-28 Pfizer Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
GEP20033006B (en) * 1995-10-31 2003-07-10 Schering Corp Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
JP2000508659A (ja) * 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
US6673831B1 (en) 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
AU4228997A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
US6235706B1 (en) * 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6251852B1 (en) * 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
EP1089731A4 (en) 1998-06-24 2003-06-18 Merck & Co Inc COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
CA2336192A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for treating elevated blood cholesterol
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
JP2000109882A (ja) * 1998-10-01 2000-04-18 Nof Corp 油性粉末、製造方法および用途
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
EP1161236A1 (en) 1999-03-08 2001-12-12 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU764048B2 (en) 1999-03-08 2003-08-07 Merck & Co., Inc. Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
ES2249253T3 (es) 1999-03-10 2006-04-01 G.D. Searle Llc Metodo y composicion para administrar un inhibidor de la ciclooxigenasa-2.
JP2000302672A (ja) * 1999-04-16 2000-10-31 Taisho Pharmaceut Co Ltd 咀嚼可能な被覆錠剤
JP3732039B2 (ja) * 1999-05-21 2006-01-05 三菱化学フーズ株式会社 錠剤用組成物
UA72922C2 (uk) 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
US6328995B1 (en) * 1999-09-24 2001-12-11 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form and process for their production
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
BRPI0108435B8 (pt) 2000-02-29 2021-05-25 Bristol Myers Squibb Co formulação e uso de entecavir de baixa dose
AU2001288724A1 (en) * 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2432798C (en) * 2000-12-20 2007-02-27 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ES2326158T3 (es) * 2000-12-28 2009-10-02 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol y su utilizacion como medicamentos.
RS51449B (sr) 2001-01-26 2011-04-30 Schering Corporation Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
CZ20032031A3 (cs) 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
NZ542090A (en) 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
CA2434430A1 (en) 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
US20030053981A1 (en) 2001-01-26 2003-03-20 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
BRPI0208384B1 (pt) 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa

Also Published As

Publication number Publication date
KR20050045993A (ko) 2005-05-17
US20070160666A1 (en) 2007-07-12
DK1531805T3 (da) 2008-07-07
ATE393628T1 (de) 2008-05-15
PA8577901A1 (es) 2004-10-08
US7229982B2 (en) 2007-06-12
EA200500279A1 (ru) 2005-06-30
HRP20080518A2 (en) 2009-03-31
IS7637A (is) 2005-01-10
AR040588A1 (es) 2005-04-13
ES2303603T3 (es) 2008-08-16
EP1531805A1 (en) 2005-05-25
BR0312933A (pt) 2005-07-12
CN101069684A (zh) 2007-11-14
MY148689A (en) 2013-05-31
AU2003261217B2 (en) 2009-06-04
US7718643B2 (en) 2010-05-18
PE20050128A1 (es) 2005-03-22
TW200412944A (en) 2004-08-01
ME00008B (me) 2010-02-10
MEP30808A (en) 2010-10-10
DE60320652T2 (de) 2009-06-10
EP1531805B1 (en) 2008-04-30
US20040126423A1 (en) 2004-07-01
CN1310643C (zh) 2007-04-18
SI1531805T1 (sl) 2008-08-31
EP1992343A1 (en) 2008-11-19
HK1080384A1 (en) 2006-04-28
NZ537611A (en) 2007-04-27
RS20050061A (en) 2007-09-21
GT200300149AA (es) 2009-07-09
UA82489C2 (uk) 2008-04-25
PT1531805E (pt) 2008-06-19
TNSN05022A1 (en) 2007-05-14
MA27289A1 (fr) 2005-04-01
WO2004010993A1 (en) 2004-02-05
US20090253675A1 (en) 2009-10-08
AU2009200768A1 (en) 2009-03-19
ZA200500196B (en) 2006-07-26
KR20080070089A (ko) 2008-07-29
RS50419B (sr) 2009-12-31
ME00207B (me) 2011-02-10
IL191348A0 (en) 2008-11-03
PL375065A1 (en) 2005-11-14
NO20051033L (no) 2005-04-25
GEP20084443B (en) 2008-08-10
MXPA05001004A (es) 2005-05-16
ECSP055573A (es) 2005-04-18
US20080275020A1 (en) 2008-11-06
MEP4708A (xx) 2010-02-10
AU2003261217A1 (en) 2004-02-16
AR067030A2 (es) 2009-09-30
CR9767A (es) 2008-04-10
IL166279A0 (en) 2006-01-15
RS20080072A (en) 2008-11-28
JP2005538104A (ja) 2005-12-15
TW200906388A (en) 2009-02-16
CN1671376A (zh) 2005-09-21
DE60320652D1 (de) 2008-06-12
GT200300149A (es) 2004-03-04
CA2493076A1 (en) 2004-02-05
NO20082156L (no) 2005-04-25
JP2008291034A (ja) 2008-12-04
EA008888B1 (ru) 2007-08-31
HRP20050081A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
ECSP085573A (es) COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCOMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE TASA Y UN AGENTE ESTABILIZANTE
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
ATA244992A (de) Stabilisiertes pharmazeutisches mittel, enthaltend einen hmg-coa-reduktase-inhibitor wirkstoff
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
PT1560826E (pt) Compostos piridopirimidinona, seus processos de preparacao e composicoes farmaceuticas que os contem
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
DE602005010203D1 (de) Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol
DE60019947D1 (de) Vorbeugung von kolorektalkrebs
RS51578B (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING TELITROMYCIN
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines
BRPI0407850A (pt) processo para fabricação de uma composição farmacêutica contendo o princìpio ativo fenofibrato ou de um de seus derivados, e, comprimido de fenofibrato ou de um de seus derivados
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
EP1652525A4 (en) ANTI-CORONAVIRUS MEDICINE
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
ES2421520T3 (es) Potenciador de la producción de adiponectina
ES2165509T3 (es) Composiciones terapeuticas efervescentes.
DOP2003000676A (es) Formulacion farmaceutica
RU2002129335A (ru) Ирригационный раствор для офтальмологии
TH62247A (es)
TH77076B (th) สารผสมตามสูตรทางเภสัชกรรม
ITTO20021048A1 (it) 3-acil derivati di 4-idrossicumarina e suoi isosteri ad attivita&#39; antibiotica.
TH85500B (th) สิ่งผสมรวมทางเภสัชกรรมสำหรับรักษาการติดเชื้อไวรัส
AR038360A4 (es) Rejilla para ventilacion con malla